GELDANAMYCIN, 17-DEMETHOXY-17-(2-PROPENYLAMINO)-
Childhood Desmoplastic Small Round Cell Tumor
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Childhood Desmoplastic Small Round Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Fludarabine St. Jude Children's Research Hospital | Phase 2 | B |
Imatinib National Cancer Institute (NCI) | Phase 2 | B |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 2 | CCC |
Evomela M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 30 →
Same molecule, other indications
GELDANAMYCIN, 17-DEMETHOXY-17-(2-PROPENYLAMINO)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →